NCT05308927

French Registry of Children Treated With Norditropin® for Short Stature Associated With Noonan Syndrome

• Status: Enrolling By Invitation
• Phase: —
• Study type: Observational
• Enrollment: 221 (estimated)
• Sponsor: Novo Nordisk A/S · Industry
• Sex: All
• Age: —
• Healthy volunteers: Not accepted

Summary

This is a non-interventional registry of children treated with Norditropin® for short stature due to Noonan Syndrome (NS). This study aims to provide data on long-term growth evolution and safety of Norditropin® as well as Health Related Quality of Life (HRQoL) data. This registry will include the entirety of children treated with Norditropin® for short stature due to NS over the inclusion period. The decision to initiate treatment with commercially available Norditropin® is made by the patient/parents/Legally Acceptable Representative (LAR) and the treating physician before and independently from the decision to include the patient in this study.

Conditions

• Noonan Syndrome

Interventions

Type	Name	Description
DRUG	Norditropin	Patients will be treated with commercially available Norditropin® according to routine clinical practice at the discretion of the treating physician.

Timeline

• Start date: 2022-03-16
• Primary completion: 2028-03-17
• Completion: 2028-03-17
• First posted: 2022-04-04
• Last updated: 2025-09-25

Locations

3 sites across 1 country: France